Back

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Biomarkers to guide the treatment of heart failure: where are we going? Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yuling Yu

Leuven (Belgium)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on biomarkers to guide the treatment of heart failure: where are we going?
Professor J. Januzzi (Boston, US)
Slides Video
Presentation thumbnail
Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials
Doctor T. Kondo (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Heart failure and renal outcomes in patient treated with GLP1 agonists.
Doctor N. del-Cuerpo-Salinas (Sant Joan d'Alacant, ES)
Abstract Slides Video
Presentation thumbnail
Liver function tests in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial
Doctor P. Myhre (Oslo, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Biomarkers to guide the treatment of heart failure: where are we going?
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources